Posted by SLS on July 22, 2012, at 9:59:39
Cariprazine is sort of like a somewhat more potent version of Abilify. Unfortunately, it seems that it shares with Abilify a potential to produce similar side effects. The stuff works, but it doesn't seem to offer any advantages over Abilify. I was hoping that there would be fewer metabolic issues, including weight gain and elevation of triglycerides. However, the differences between these two drugs that do exist might result in cariprazine being a better match for some people than Abilify. Of course, experience in the field would reveal this. I am in favor of having more tools to work with rather than less. I'm not so sure about this one, though.
I would like to see a D2/D3 postsynaptic receptor partial agonist that doesn't act as a full agonist presynaptically at the same time. It might be better suited for treating depression. Then again, more might be less. Such a drug could be destabilizing. I haven't researched the matter.
"APA 2012: cariprazine fails to offer a therapeutic breakthrough"
"At least one common treatment-emergent adverse event was experienced by 66.7% of patients, with the most common side effects including akathisia (14.0%), insomnia (14.0%), and weight gain (11.8%). Worryingly for Forest, a total of 17 different side effects had an incidence of 5% or more during the extension period, with metabolic issues, extrapyramidal side effects, and sedation all featuring.
Some see things as they are and ask why.
I dream of things that never were and ask why not.
- George Bernard Shaw